Abstract
O-1602 is a cannabidiol analogue that does not bind with high affinity to either the cannabinoid CB1 receptor or CB2 receptor. However, there is evidence that O-1602 has significant effects in the central nervous system as well as other parts of the body. Depending upon the model, O-1602 has anti-inflammatory or pronociceptive effects, mediated through a number of distinct receptors. This article reviews the evidence for functional effects of O-1602, particularly in the CNS, and describes its known targets as they relate to these effects. These include the abnormal cannabidiol (Abn- CBD) receptor and GPR55. The GPR18 receptor has been identified with the Abn-CBD receptor, and therefore the evidence that O-1602 also acts at GPR18 is also reviewed. Finally, the evidence that these receptor targets are expressed in the CNS and the phenotypes of cells expressing these targets is discussed, concluding with a discussion of the prospects for O-1602 as a therapeutic agent in the CNS.
Keywords: Abnormal Cannabidiol, Cannabidiol, Cannabinoid, inflammation, GPR18, GPR55, O-1602, microglia.
Central Nervous System Agents in Medicinal Chemistry
Title:The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System
Volume: 12 Issue: 3
Author(s): John C. Ashton
Affiliation:
Keywords: Abnormal Cannabidiol, Cannabidiol, Cannabinoid, inflammation, GPR18, GPR55, O-1602, microglia.
Abstract: O-1602 is a cannabidiol analogue that does not bind with high affinity to either the cannabinoid CB1 receptor or CB2 receptor. However, there is evidence that O-1602 has significant effects in the central nervous system as well as other parts of the body. Depending upon the model, O-1602 has anti-inflammatory or pronociceptive effects, mediated through a number of distinct receptors. This article reviews the evidence for functional effects of O-1602, particularly in the CNS, and describes its known targets as they relate to these effects. These include the abnormal cannabidiol (Abn- CBD) receptor and GPR55. The GPR18 receptor has been identified with the Abn-CBD receptor, and therefore the evidence that O-1602 also acts at GPR18 is also reviewed. Finally, the evidence that these receptor targets are expressed in the CNS and the phenotypes of cells expressing these targets is discussed, concluding with a discussion of the prospects for O-1602 as a therapeutic agent in the CNS.
Export Options
About this article
Cite this article as:
C. Ashton John, The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System, Central Nervous System Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152412802430156
DOI https://dx.doi.org/10.2174/187152412802430156 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study
Current Alzheimer Research CSF Ubiquitin As a Specific Biomarker in Alzheimer's Disease
Current Alzheimer Research Adult Stem Cell Therapy for Acute Brain Injury in Children
CNS & Neurological Disorders - Drug Targets Lactones: Generic Inhibitors of Enzymes?
Mini-Reviews in Medicinal Chemistry Interlocked Systems in Nanomedicine
Current Topics in Medicinal Chemistry Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke
Current Medicinal Chemistry 3-Phenyl-1H-Indole-5-Sulfonamides: Structure-Based Drug Design of a Promising Class of Carbonic Anhydrase Inhibitors
Current Pharmaceutical Design Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Mst1: Function and Mechanism in Brain and Myocardial Ischemia Reperfusion Injury
Current Neuropharmacology Effects of Static Magnetic Fields on Blood Pressure in Animals and Humans
Current Hypertension Reviews New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?
Current Pharmaceutical Design Neuroglobin and Estrogen Receptors: A New Pathway of Cell Survival and Cell Death Balance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial: Targeting Cerebral Vascular Injury for Intervention
Current Drug Delivery Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Amyloid Beta: The Alternate Hypothesis
Current Alzheimer Research Host-Pathogen Interactions and the Pathological Consequences of Acute Systemic Candida albicans Infections in Mice
Current Drug Targets Homocysteine and Cerebral Stroke in Developing Countries
Current Medicinal Chemistry